跳转至内容
Merck
CN

A0152000

乙酰半胱氨酸杂质C

European Pharmacopoeia (EP) Reference Standard

别名:

N,N′-二乙酰基-L-胱氨酸, NSC 203780

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C10H16N2O6S2
CAS号:
分子量:
324.37
EC 号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

acetylcysteine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

InChI

1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)

InChI key

YTPQSLLEROSACP-UHFFFAOYSA-N

一般描述

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括 SDS 和任何产品信息小册子,均由药典颁发机构制定和发布。

如需进一步信息和支持,请访问现行药典网站。

应用

本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途,用户请自行负责。本标准品不适用于人类或动物使用。
用于制备参考溶液 (c),根据欧洲药典各论 0967,使用气相色谱法(通则 2.2.28)测试乙酰半胱氨酸中的相关物质。

包装

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

其他说明

可能适用相应的销售限制。

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Knut S Pettersson et al.
Basic & clinical pharmacology & toxicology, 100(1), 36-42 (2007-01-12)
N,N-diacetyl-L-cystine (DiNAC), a novel immunomodulator, stimulates contact sensitivity/delayed type hypersensitivity reactions in mice induced by oxazolone and reduces atherosclerosis in Watanabe heritable hyperlipidaemic (WHHL) rabbits. Forty-week-old WHHL rabbits were given DiNAC (3 micromol/kg per day) for 8 weeks, and endothelium-mediated
Sheila A Doggrell
Expert opinion on investigational drugs, 11(5), 717-720 (2002-05-09)
Not all antioxidants reduce atherosclerosis. This may be because atherosclerosis has an autoimmune, inflammatory pathogenesis. As probucol is both an antioxidant and an immunomodulatory drug, it may be the immunomodulatory effect that underlies its ability to reduce atherosclerosis. N,N-Diacetyl-L-cystine is
Acetylcysteine
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4900-4901 (2021)
Knut Pettersson et al.
Cardiovascular drug reviews, 21(2), 119-132 (2003-07-09)
Inflammatory processes in the arterial wall are important in atherogenesis. The present review discusses the development of DiNAC as a potential new treatment modality for atherosclerosis related diseases. DiNAC, N,N'-diacetyl-L-cystine, is the disulphide dimer of N-acetyl cysteine, NAC. It was
S Boräng et al.
Gene, 271(2), 183-192 (2001-06-22)
In this study, we have applied and evaluated a modified cDNA representational difference analysis (RDA) protocol based on magnetic bead technology to study the molecular effects of a candidate drug (N,N'-diacetyl-L-cystine, DiNAC) in a model for atherosclerosis. Alterations in a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门